Yasuomi Ouchi Selected Research

N-methyl-3-piperidyl benzilate

1/2012

Reduction of [11C](+)3-MPB binding in brain of chronic fatigue syndrome with serum autoantibody against muscarinic cholinergic receptor.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Yasuomi Ouchi Research Topics

Disease

11	Alzheimer Disease (Alzheimer's Disease) 01/2020 - 08/2009
7	Autistic Disorder (Autism) 01/2022 - 04/2007
7	Cognitive Dysfunction 01/2022 - 04/2013
7	Parkinson Disease (Parkinson's Disease) 01/2022 - 06/2002
6	Dementia (Dementias) 01/2021 - 02/2011
5	Autism Spectrum Disorder 01/2022 - 03/2011
5	Neuroinflammatory Diseases 01/2021 - 01/2017
4	Parkinsonian Disorders (Parkinsonism) 09/2010 - 01/2007
3	Mitochondrial Diseases (Mitochondrial Disease) 01/2022 - 03/2002
3	Atrophy 01/2022 - 12/2013
2	Amyloid Plaque 08/2015 - 02/2011
2	Cerebellar Ataxia (Dysmetria) 12/2014 - 12/2013
2	Chronic Fatigue Syndrome (Myalgic Encephalomyelitis) 01/2012 - 12/2004
2	Gaucher Disease (Gaucher's Disease) 09/2010 - 01/2007
1	Neurodevelopmental Disorders 01/2021
1	Attention Deficit Disorder with Hyperactivity (Attention Deficit Hyperactivity Disorder) 01/2021
1	Bulimia (Binge Eating) 01/2019
1	Gambling (Pathological Gambling) 01/2019
1	Anorexia Nervosa 01/2019
1	Multiple Sclerosis 01/2018
1	Infarction (Infarctions) 01/2017
1	Stroke (Strokes) 01/2017
1	Migraine with Aura (Familial Hemiplegic Migraine) 12/2014
1	Spinocerebellar Ataxias (Spinocerebellar Ataxia) 12/2014
1	Nervous System Diseases (Neurological Disorders) 12/2014
1	autosomal dominant Spastic paraplegia 3 04/2013
1	Hereditary Spastic Paraplegia 04/2013
1	Dyskinesias (Dyskinesia) 01/2013
1	Chorea (Rheumatic Chorea) 01/2013
1	Mental Disorders (Mental Disorder) 01/2012
1	Brain Injuries (Brain Injury) 11/2009
1	Squamous Cell Neoplasms (Squamous Cell Cancer) 04/2009
1	Normal Pressure Hydrocephalus 04/2007
1	Neoplasms (Cancer) 06/2006
1	Cerebrovascular Disorders (Cerebrovascular Occlusion) 05/2004
1	Non-Hodgkin Lymphoma (Lymphosarcoma) 01/2004
1	Hodgkin Disease (Hodgkin's Disease) 01/2004
1	Lymphoma (Lymphomas) 01/2004
1	Ovarian Neoplasms (Ovarian Cancer) 06/2002

Drug/Important Bio-Agent (IBA)

9	Glucose (Dextrose)FDA LinkGeneric 01/2022 - 08/2009
8	Amyloid (Amyloid Fibrils)IBA 01/2022 - 02/2011
7	Serotonin (5 Hydroxytryptamine)IBA 01/2020 - 12/2004
6	Dopamine (Intropin)FDA LinkGeneric 01/2022 - 06/2002
4	2- (4'- (methylamino)phenyl)- 6- hydroxybenzothiazole (Pittsburgh compound B)IBA 01/2022 - 02/2011
4	PK 11195 (PK11195)IBA 01/2021 - 12/2009
4	Serotonin Plasma Membrane Transport Proteins (Serotonin Transporter)IBA 01/2019 - 10/2008
4	Cholinergic Agents (Cholinergics)IBA 01/2018 - 01/2012
3	N- (4'- fluorobutyrophenone)- 4- (4- chlorophenyl)pyridinium (HPP(+))IBA 01/2022 - 01/2021
3	Proteins (Proteins, Gene)FDA Link 03/2017 - 02/2011
3	GABA-A Receptors (GABA(A) Receptor)IBA 12/2014 - 11/2009
3	DNA (Deoxyribonucleic Acid)IBA 12/2008 - 09/2007
3	Deoxyglucose (2 Deoxy D glucose)IBA 06/2006 - 06/2002
2	gamma-Aminobutyric Acid (GABA)IBA 01/2022 - 12/2013
2	Dopamine Plasma Membrane Transport Proteins (Dopamine Transporter)IBA 12/2021 - 01/2010
2	Cannabinoid Receptors (Cannabinoid Receptor)IBA 11/2019 - 01/2017
2	Nicotinic Receptors (Nicotinic Acetylcholine Receptor)IBA 01/2018 - 10/2013
2	Oxytocin (Pitocin)FDA LinkGeneric 09/2017 - 05/2017
2	Messenger RNA (mRNA)IBA 04/2013 - 04/2007
2	Glucosylceramidase (Glucocerebrosidase)IBA 09/2010 - 01/2007
2	Neurotransmitter Agents (Neurotransmitter)IBA 01/2010 - 12/2004
2	Pharmaceutical PreparationsIBA 12/2009 - 04/2007
2	FluorineIBA 01/2004 - 06/2002
1	Aminobutyrates (Aminobutyric Acid)IBA 01/2022
1	Adenosine Triphosphate (ATP)IBA 12/2021
1	Dopamine D1 Receptors (Dopamine D1 Receptor)IBA 01/2021
1	Methylphenidate (Ritalin)FDA LinkGeneric 01/2021
1	SCH 23390IBA 01/2021
1	AN 12IBA 01/2019
1	3- amino- 4- (2- dimethylaminomethylphenylsulfanyl)benzonitrileIBA 01/2019
1	2- oxo- 7- methoxy- 8- butyloxy- 1,2- dihydroquinoline- 3- carboxylic acid cyclohexylamideIBA 01/2017
1	4- (N- methylamino)- 4'- (2- (2- (2- fluoroethoxy)ethoxy)ethoxy)stilbeneIBA 08/2015
1	Amyloid beta-PeptidesIBA 08/2015
1	Calcium Channels (Calcium Channel)IBA 12/2014
1	Flumazenil (Romazicon)FDA LinkGeneric 12/2013
1	AntibodiesIBA 12/2013
1	Glutamate Decarboxylase (Decarboxylase, Glutamate)IBA 12/2013
1	Intravenous Immunoglobulins (IVIG)FDA Link 12/2013
1	Dopamine D2 Receptors (Dopamine D2 Receptor)IBA 01/2013
1	Levodopa (L Dopa)FDA LinkGeneric 01/2013
1	Haloperidol (Haldol)FDA LinkGeneric 01/2013
1	Amyloidogenic ProteinsIBA 02/2012
1	N-methyl-3-piperidyl benzilateIBA 01/2012
1	AutoantibodiesIBA 01/2012
1	Cholinergic ReceptorsIBA 01/2012
1	AcetylcholinesteraseIBA 03/2011
1	Fluorodeoxyglucose F18 (Fludeoxyglucose F 18)FDA Link 04/2009
1	Syntaxin 1IBA 12/2008
1	Intercellular Signaling Peptides and Proteins (Growth Factors)IBA 09/2007
1	Epidermal Growth Factor (EGF)IBA 09/2007
1	Brain-Derived Neurotrophic Factor (BDNF)IBA 04/2007
1	Oxygen (Dioxygen)IBA 05/2004
1	Carbon MonoxideIBA 05/2004
1	Carbon DioxideIBA 05/2004
1	Oxygen-15IBA 05/2004
1	RacloprideIBA 06/2002

Therapy/Procedure

4	Therapeutics 01/2018 - 01/2004
2	Drug Therapy (Chemotherapy) 12/2013 - 01/2004
1	Deep Brain Stimulation 12/2021
1	Transcranial Direct Current Stimulation 01/2017
1	Secondary Prevention 01/2004